Recombinant human interleukin 28B: Anti-HCV potency, receptor usage and restricted cell-type responsiveness

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 5, 2012, Pages 1080-1087

  Cheng, Min ^a   Si, Youhui ^a   Yang, Yang ^a   Liu, Xiuying ^a   Gong, Qiaoling ^a   Zhao, Jin ^a   Niu, Yuqiang ^a   Li, Xiang ^a   Jin, Qi ^a   Yang, Wei ^a  

^a INSTITUTE OF PATHOGEN BIOLOGY   (China)

Author keywords

Interferon lambda 3; JAK STAT pathway; Pichia pastoris; Receptor distribution

Indexed keywords

ANTIVIRUS AGENT; INTERFERON; INTERLEUKIN 10 RECEPTOR; INTERLEUKIN 28B; INTERLEUKIN RECEPTOR; NEUTRALIZING ANTIBODY; PEGINTERFERON ALPHA2B; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 28B; RIBAVIRIN; STAT1 PROTEIN; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DRUG POTENCY; DRUG POTENTIATION; FEMALE; GENE EXPRESSION; GENE INDUCTION; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; ION EXCHANGE; LIVER CELL; LUNG ALVEOLUS CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PICHIA PASTORIS; PROSTATE; PROTEIN PHOSPHORYLATION; TREATMENT RESPONSE; VIRUS INHIBITION; VIRUS NEUTRALIZATION;

ANTIVIRAL AGENTS; CELL LINE; CHROMATOGRAPHY, ION EXCHANGE; DRUG SYNERGISM; GENE EXPRESSION PROFILING; HEPACIVIRUS; HEPATOCYTES; HUMANS; IMMUNOLOGIC FACTORS; INHIBITORY CONCENTRATION 50; INTERLEUKINS; PICHIA; RECOMBINANT PROTEINS; RIBAVIRIN; VIRUS REPLICATION;

EID: 84859571791     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks015     Document Type: Article

References (22)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-15.
2. O'Brien TR. Interferon-alfa, interferon-λ and hepatitis C. Nat Genet 2009; 41: 1048-50.
3. Sulkowski MS, Cooper C, Hunyady B et al. Management of adverse effects of peg-IFN and ribavirin therapy for hepatitis C. Nat Rev Gastroenterol Hepatol 2011; 8: 212-23.
4. Suppiah V, Moldovan M, Ahlenstiel G et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 2009; 41: 1100-4.
5. Tanaka Y, Nishida N, Sugiyama M et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.
6. Thomas DL, Thio CL, Martin MP et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
7. Ge D, Fellay J, Thompson AJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
8. Kelly C, Klenerman P, Barnes E. Interferon lambdas: the next cytokine storm. Gut 2011; 60: 1284-93.
9. Kotenko SV, Gallagher G, Baurin VV et al. IFN-λs mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77.
10. Witte K, Gruetz G, Volk HD et al. Despite IFN-λ receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun 2009; 10: 702-14.
11. Doyle SE, Schreckhise H, Khuu-Duong K et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006; 44: 896-906.
12. Zhou Z, Hamming OJ, Ank N et al. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 2007; 81: 7749-58.
13. Dellgren C, Gad HH, Hamming OJ et al. Human interferon-λ3 is a potent member of the type III interferon family. Genes Immun 2009; 10: 125-31.
14. Sheppard P, Kindsvogel W, Xu W et al. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 2003; 4: 63-8.
15. Ank N, West H, Bartholdy C et al. Lambda interferon (IFN-λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006; 80: 4501-9.
16. Muir AJ, Shiffman ML, Zaman A et al. Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology 2010; 52: 822-32.
17. Pietschmann T, Kaul A, Koutsoudakis G et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc Natl Acad Sci USA 2006; 103: 7408-13.
18. Liu X, Wang T, Wakita T et al. Systematic identification of microRNA and messenger RNA profiles in hepatitis C virus-infected human hepatoma cells. Virology 2010; 398: 57-67.
19. Zhang L, Jilg N, Shao RX et al. IL28B inhibits hepatitis C virus replication through the JAK-STAT pathway. J Hepatol 2010; 55: 289-98.
20. McHutchison JG, Lawitz EJ, Shiffman ML et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-93.
21. Marcello T, Grakoui A, Barba-Spaeth G et al. Interferons a and λ inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 2006; 131: 1887-98.
22. Siren J, Pirhonen J, Julkunen I et al. IFN-a regulates TLR-dependent gene expression of IFN-α, IFN-β, IL-28, and IL-29. J Immunol 2005; 174: 1932-7.